19th Annual Cancer Progress Conference
March 11-12, 2008

Note: The 2009 program will be posted soon

Moderators:  Jeremy P. Goldberg
                   
Managing Director, Corporate Development
                    Endo Pharmaceuticals

                    Mark J. Simon
                   
Industry Consultant
                    Williver Group, LLC


Keynote Presentation: Targeting the Ras Pathway
                    Frank McCormick, Ph.D., FRS   
   
                Director
                    UCSF
Comprehensive Cancer Center


Special Presentation: MicroRNAs Can Turn Off The Growth of Cancer Cells - Implications for Cancer Therapy
        
           Scott W. Lowe, Ph.D.
   
                     Professor, Cold Spring Harbor Laboratory
                    Deputy Director, Cold Spring Harbor Laboratory Cancer Center
                    HHMI Investigator


Special Presentation: Combinatorial Approaches in Molecular Targeted Therapies – 
         Rationale for Multi-Targeting in Cancer
                
   Scott E. Kern, M.D.
                    Professor of Oncology
                    The Sidney Kimmel Cancer Center at Johns Hopkins

Panel Discussion: Targeted Therapies – Where Are We Now?  
   Moderator:     Richard E. Smith, Ph.D.
   
                    
Vice President & Senior Biotechnology Analyst
                         JP Morgan

    Panelists:      Bruce A. Chabner, M.D.
   
                    Clinical Director
                       Massachusetts General Hospital Cancer Center

                       David Heimbrook, Ph.D.
   
                    Vice President, Research
   
                         Disease Biology Area Head, Discovery Oncology
                       Roche

                       Carlos L. Arteaga, M.D.
   
                         Professor of Medicine and Cancer Biology
                       Director, VICC Breast Cancer Program, Division of Oncology
                       Vanderbilt-Ingram Cancer Center

Panel Discussion: Biomarkers - Are We There Yet? 

    Moderator:    Pearl S. Huang, Ph.D.
   
                      Vice President, Franchise Integrator, Oncology
                         Merck & Co.

     Panelists:     Samir Khleif, Ph.D.
   
                     Chief, Cancer Vaccine Section
   
                          National Cancer Institute

                        David R. Parkinson, M.D.
   
                     President & CEO
                        Nodality, Inc.

                        Nicholas Dracopoli, Ph.D.
                        Vice President, Biomarkers
                        Centocor Research & Development, Inc.

                        Donald A. Bergstrom, M.D., Ph.D.
                        Director, Experimental Medicine - Oncology
                        Merck & Co., Inc.

                        Mark J. Ratain, M.D.
   
                     Chairman, Committee on Clinical Pharmacology & Pharmacogenomics
                        Leon O. Jacobson, Professor of Medicine, Cancer Research Center
                        University of Chicago

                        Colin Hill
                        CEO
                        Gene Network Sciences


Panel Discussion: New Strategies to Mitigate High Attrition Rates in Oncology Drug Development 
    Moderator:     Richard Gaynor, M.D.
   
                      Vice President Cancer Research and Clinical Investigation
                         Eli Lilly & Company

    Panelists:      Ira Mellman, Ph.D.
   
                          Vice President, Oncology Research
                        Genentech

                        Ian Taylor, Ph.D.
   
                     Director, Translational Medicine, Oncology
                        Pfizer PGRD

                        Peter T. Ho, M.D., Ph.D.
   
                     Senior Vice President, Oncology CEDD
                        GlaxoSmithKline Pharmaceuticals Corp.

                        Catherine A. Wheeler, M.D.
   
                     Executive Director, Oncology Clinical Development
                        Roche

 
Panel Discussion:  Genes Set The Stage for Metastasis – Targets for Therapeutic Intervention
   Moderator:     Gregory K. Frykman, M.D.
   
                      Senior Vice President, Pharmaceuticals and Biotechnology
                         Stanford Washington Research Group

    Panelists:       Joan Massague, Ph.D.
   
                      Chairman, Cancer Biology and Genetics Program, HHMI
                         Memorial-Sloan Kettering Cancer Center

                         Yibin Kang, Ph.D.
                        
Assistant Professor of Molecular Biology
                         Princeton University


Targeting Cell Death/Apoptosis
   
                         Douglas R. Green, Ph.D.
   
                    Doherty Chair of Immunology, Department of Immunology
                       St. Jude Children’s Research Hospital

New Horizons In Therapeutic Intervention for Hematologic Neoplasias
   
                         Kenneth Anderson, M.D.
   
                    Program Director, Hematologic Neoplasias
                       Dana Farber Cancer Institute


Value Based Pricing for Oncology Drugs, including the Role of Biomarkers In Pricing – 
Will They Help to Set Price Points, Affect Reimbursement?
   
                         Lee Blansett
   
                    Vice President
                       DaVinci Oncology Specialists, a Unit of The Mattson Jack Group


An Update on FDA Regulations
   
                         Daniel Troy, Esq.
   
                     Former Chief Counsel, FDA
   
                     Partner
                        Sidley Austin LLP
                    

Panel Discussion:  Immunotherapy of Cancer – What’s Working – What’s Not? Is it Clinical Design?
        If we need to go very personalized, will Big Pharma walk away?

    Moderator:       Michael T. Lotze, M.D.
                            Professor of Surgery & Bioengineering
                            Assistant Vice Chancellor 
                            University of Pittsburgh SHS
                            Associate Director, Strategic Partnerships
                            University of Pittsburgh Cancer Institute

    Panelists:          Elizabeth M. Jaffee, M.D.
   
                         The Dana and Albert (Cubby) Broccoli Professor of Oncology
                            Co-Director, Division of Immunology and Hematologic Malignancies
                            Co-Director, Gastrointestinal Cancers Program
                            Sidney Kimmel Cancer Center at Johns Hopkins

                            Vincent T. Brichard, M.D., Ph.D.
   
                         Vice President Cancer Immunotherapeutics
                            GlaxoSmithKline

                            Carl H. June, M.D.
   
                         Director, Translational Research
                            Abramson Cancer Center
                            Professor of Pathology and Laboratory Medicine
                            University of Pennsylvania

                            Mark Vincent, M.D.
                            Director, Investigational Oncology
                            Chair, Scientific Advisory Board
                            YM Biosciences

                            David Berd, M.D.
                            Chief Medical Officer
                            AVAX Technologies


Panel Discussion:  Dealmaking in Oncology – What is Big Pharma Looking For?
    Moderator:       Roger Longman
   
                         Managing Partner
                            Windhover Information

    Panelists:          George Golumbeski, Ph.D.
   
                         Vice President, Business Development & Licensing / Strategy
                            Novartis

                            Thomas Hofstaetter, Ph.D.
                            Senior Vice President, Corporate Business Development
                            Wyeth

                            Mervyn J. Turner, Ph.D.
   
                         Senior Vice President, Worldwide Licensing & External Research
                            Merck & Co.
                            Merck Research Laboratories

                            Warwick S. Bedwell
                            Vice President and Global Head, Business Development - Pharma Partnering
                            Roche

                            Dr. Daniel Teper
   
                         Managing Director, North America
                            Bionest Partners


The Future of Cytotoxic Chemotherapy - Is the field dead or alive?
   
                             Robert Kramer, Ph.D.
   
                       Vice President Biology Drug Discovery
                          Bristol-Myers Squibb


An Update on New Therapeutics for Prostate Cancer
   
                             Philip Kantoff, M.D.
   
                       Chief Clinical Research Officer
                          Chief, Division of Solid Tumor Oncology
                          Director, Lank Center for Genitourinary Oncology
                          Dana-Farber Cancer Institute
                          Professor of Medicine
                          Harvard Medical School


2009 Conference Discussion        Communitech